510(k) device
Sonablate
Sonacare Medical, LLC · High Intensity Ultrasound System For Prostate Tissue Ablation (PLP, Class II) · First FDA decision Dec 21, 2016, newest Dec 21, 2016Prostate cancer
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
9
Naming "Sonablate"
MAUDE reports
26
Brand "Sonablate", since 2015
PubMed studies
58
Mentioning "Sonablate"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Sonablate
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Sonablate510(k)
K160942 · Decided Dec 21, 2016 · 260 days after receipt
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
- Laser Ablation of the ProstateLocal determinationIn effectL34090CGS Administrators, LLCUpdated Mar 25, 2026
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38705Noridian Healthcare Solutions, LLCUpdated Feb 23, 2026
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38549Palmetto GBAUpdated Oct 24, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38682WPS Insurance CorporationUpdated Oct 21, 2025
- Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for TremorProposed local determinationProposedDL37421National Government Services, Inc.Updated Sep 18, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38726First Coast Service Options, Inc.Updated Mar 14, 2025
- Transurethral Waterjet Ablation of the ProstateLocal determinationIn effectL38712Novitas Solutions, Inc.Updated Mar 14, 2025
Clinical trials
Device studies on ClinicalTrials.gov that name "Sonablate", any status and sponsor, newest update first.
SonablateNot on our public-company list
NCT07757490 · 10,000 participants (planned) · Start Jan 1, 2015 · Primary completion Dec 2035
Device: High Intensity Focused Ultrasound · For: Localized Prostate Cancer; BPH (Benign Prostatic Hyperplasia); Prostate Cancer; Benign Prostatic Hyperplasia
Sites: Indianapolis, Indiana
8 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Sonablate", and for the whole product code for context.
This brand
26 reports: 1 malfunction, 24 injury, 1 death
Whole product code PLP
33 reports: 1 malfunction, 31 injury, 1 death
Newest reports for this brand
- SONABLATEInjury
2951226-2026-00003 · Received Jul 17, 2026 · Event dated Apr 21, 2026
Device type: High Intensity Ultrasound System For Prostate Tissue Ablation (PLP)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Fistula
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Sonablate"[tiab]. The summary above synthesizes these.
- High-Intensity Focused Ultrasound (Sonablate®) for Prostate Cancer: Preliminary Outcomes in Taiwan.
Tsai MY, Lin CT, Chiang PH, et al. · Ann Surg Oncol · 2023
- Focal High-Intensity Focused Ultrasound Ablation of the Prostate.
Abrams LR, Koch MO, Bahler CD · J Endourol · 2021
- An Exploratory Study of Dose Escalation vs Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer.
Huber PM, Afzal N, Arya M, et al. · J Endourol · 2020Research Support, Non-U.S. Gov't
- Sonablate-500: transrectal high-intensity focused ultrasound for the treatment of prostate cancer.
Illing R, Emberton M · Expert Rev Med Devices · 2006Research Support, Non-U.S. Gov't, Review
- ASO Author Reflections: High-Intensity Focused Ultrasound will Become the Routine Practice for Treatment of Localized Prostate Cancer.
Tsai MY, Lin CT, Chiang PH, et al. · Ann Surg Oncol · 2023
- Sonablate-500 transrectal high-intensity focused ultrasound (HIFU) for benign prostatic hyperplasia patients.
Lü J, Hu W, Wang W · J Huazhong Univ Sci Technolog Med Sci · 2007Evaluation Study, Research Support, Non-U.S. Gov't
- High-intensity focused ultrasound energy for benign prostatic hyperplasia: clinical response at 6 months to treatment using Sonablate 200.
Nakamura K, Baba S, Saito S, et al. · J Endourol · 1997
- Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy.
Uddin Ahmed H, Cathcart P, Chalasani V, et al. · Cancer · 2012Research Support, Non-U.S. Gov't
- Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.
Reddy D, Peters M, Shah TT, et al. · Eur Urol · 2022Research Support, Non-U.S. Gov't
- Focal HIFU therapy for anterior compared to posterior prostate cancer lesions.
Huber PM, Afzal N, Arya M, et al. · World J Urol · 2021Comparative Study
- Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer.
Kanthabalan A, Peters M, Van Vulpen M, et al. · BJU Int · 2017
- A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
Guillaumier S, Peters M, Arya M, et al. · Eur Urol · 2018Multicenter Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code PLP.
- TULSA-PRO SystemProfound Medical, Inc. · 510(k) 2023
- Focal One®Edap Technomed, Inc. · 510(k) 2025
- Exablate Model 2100V1Insightec, Ltd. · 510(k) 2023
- Tulsa Pro System (Pad-105)Profound Medical, Inc. · 510(k) 2024
- Ablatherm FusionEdap Technomed, Inc. · 510(k) 2017
- Ablatherm Integrated ImagingEdap Technomed, Inc. · 510(k) 2015
- Sonablate 450Sonacare Medical, LLC · De Novo 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.